VOLUNTARY ANNOUNCEMENT - UPGRADE TO AA IN MSCI ESG RATINGS

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TRD221 "COMPLEMENT PROTEIN MODULATOR" APPROVED BY THE NMPA

NOTIFICATION OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III CLINICAL STUDY OF TQB3454 "IDH1 INHIBITOR" FOR BILIARY TRACT CANCER

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB3205 “PAN-KRAS INHIBITOR” APPROVED BY THE NMPA

VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026

VOLUNTARY ANNOUNCEMENT - “ROVADICITINIB TABLET” APPROVED FOR MARKETING